1478-3231/asset/LIV_left.gif?v=1&s=85fae709761c931e1b1f055c02ebb481958f0f73)
You have free access to this content
Hepatitis B virus resistance to antiviral drugs: where are we going?
Article first published online: 4 JAN 2011
DOI: 10.1111/j.1478-3231.2010.02399.x
© 2011 John Wiley & Sons A/S
Issue
Liver International
Special Issue: Proceedings of the 4th Paris Hepatitis Conference. The publication of this supplement was supported by an unrestricted educational grant from F. Hoffmann-Laroche Ltd.
Volume 31, Issue Supplement s1, pages 111–116, January 2011
Additional Information
How to Cite
Zoulim, F. (2011), Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver International, 31: 111–116. doi: 10.1111/j.1478-3231.2010.02399.x
Publication History
- Issue published online: 4 JAN 2011
- Article first published online: 4 JAN 2011
- Received 10 November 2010Accepted 25 November 2010
References
- 1, Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl. 1): S2–19.
- 2European Association for the study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–42.
- 3
- 4, , , et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006; 295: 65–73.
- 5, , , et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–31.
- 6, , , et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology.
- 7, , , et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–55.
- 8, , , et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–51.
- 9, , , et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105–17.
- 10, , , et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–17.
- 11, , , et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–95.
- 12, Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593–608.
- 13, , , et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687–96.
- 14, , , et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714–22.
- 15, , , et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750–8.
- 16, , , et al. 2-Year GLOBE Trial Results: Telbivudine is superior to Lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486–95.
- 17, , , et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422–30.
- 18, , , et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078–88.
- 19, , , et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883–91.
- 20, , , et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703–12.
- 21, , , , Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253–61.
- 22, , , et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531–8.
- 23, , , et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493–500.
- 24, , , et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73–80.
- 25, , , et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747–55.
- 26, , , et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–83.
- 27, Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595–7.
- 28, , , et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009; 83: 1718–26.
- 29, , , et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34 (Part 1): 785–91.
- 30, , , et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–62.
- 31, , , et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890–7.
- 32, , , et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695–703.
- 33, , , et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–14.
- 34, , Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613–22.
- 35, , , et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335–41.
- 36, , , et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823–37.
- 37, , , et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)b-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1998; 42: 3179–86.
- 38, , , et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002; 46: 3057–60.
- 39, , , et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antivir Res 2002; 54: 69–78.
- 40, , , et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893–6.
- 41, , , et al. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res 2007; 76: 30–7.
- 42, , , et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998; 4: 610–14.
- 43, , , et al. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther. 2009; 14: 792–808.
- 44, , , . Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010; 51: 63–72.
- 45, , , et al. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther 2009; 14: 131–5.
- 46, , , et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008; 205: 2111–24.
- 47, , , et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835–45.
- 48, , , et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667–80.